These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 27837044)

  • 1. Development of a systematic approach to pharmaceutical industry's patient assistance programs on accessing unfunded cancer drugs.
    Kletas V; de Lemos M
    J Oncol Pharm Pract; 2018 Jan; 24(1):18-21. PubMed ID: 27837044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approved but non-funded vaccines: accessing individual protection.
    Scheifele DW; Ward BJ; Halperin SA; McNeil SA; Crowcroft NS; Bjornson G
    Vaccine; 2014 Feb; 32(7):766-70. PubMed ID: 24374500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
    Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
    Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study.
    Grover P; Babar ZU; Oehmen R; Vitry A
    Health Policy; 2018 Mar; 122(3):243-249. PubMed ID: 29295745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation and consternation: access to unfunded cancer drugs in Canada.
    Berry SR; Evans WK; Strevel EL; Bell CM
    J Oncol Pract; 2012 Jan; 8(1):35-9. PubMed ID: 22548009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded access and patient assistance programs for other experimental drugs from their manufacturers.
    Crit Path AIDS Proj; 1997; (No 32):44-64. PubMed ID: 11364445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-office dispensing of oral oncolytics: a continuity of care and cost mitigation model for cancer patients.
    Egerton NJ
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s99-s103. PubMed ID: 27270161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to drugs for cancer: Does where you live matter?
    Menon D; Stafinski T; Stuart G
    Can J Public Health; 2005; 96(6):454-8. PubMed ID: 16350873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accessing patient assistance programs to meet clients' medication needs.
    Williams K
    J Am Acad Nurse Pract; 2000 Jun; 12(6):233-5. PubMed ID: 11930446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials.
    Tie J; Gibbs P
    Intern Med J; 2013 Jan; 43(1):23-31. PubMed ID: 22372920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach.
    Zafar SY; Peppercorn J; Asabere A; Bastian A
    J Oncol Pract; 2017 Mar; 13(3):e240-e248. PubMed ID: 28140745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical financial assistance programs for HIV drugs.
    Bowers M
    BETA; 1998 Apr; ():23-8. PubMed ID: 11365260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics.
    Mitchell A; Muluneh B; Patel R; Basch E
    J Oncol Pharm Pract; 2018 Sep; 24(6):424-432. PubMed ID: 28714357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients.
    Gao L; Joseph J; Santoro-Levy M; Multz AS; Gotlieb VK
    Hosp Pharm; 2016 Jul; 51(7):572-6. PubMed ID: 27559190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of obtaining medications from pharmaceutical company assistance programs on therapeutic goals.
    Trompeter JM; Havrda DE
    Ann Pharmacother; 2009 Mar; 43(3):469-77. PubMed ID: 19240259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary health care and donor dependency: a case study of nongovernment assistance in Burkina Faso.
    Maclure R
    Int J Health Serv; 1995; 25(3):539-58. PubMed ID: 7591380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The public funding of expensive cancer therapies: synthesizing the "3Es"--evidence, economics, and ethics.
    Kirby J; Somers E; Simpson C; McPhee J
    Organ Ethic; 2008; 4(2):97-108. PubMed ID: 18839752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.